Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Other(3)

Detailed Status

Suspended2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed125%
suspended250%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

NCT04504942
unknown

A Compassionate Use Study of Leronlimab in Breast Cancer

NCT04313075
suspendedphase_3

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

NCT04901689
suspendedphase_3

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

NCT04901676

Clinical Trials (4)

Showing 4 of 4 trials
NCT04504942Phase 2

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Completed
NCT04313075

A Compassionate Use Study of Leronlimab in Breast Cancer

Unknown
NCT04901689Phase 3

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Suspended
NCT04901676Phase 3

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

Suspended

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4